Skip to main content
SpringerLink
Log in

Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Objectives: Glioblastoma multiforme (GBM) may potentially be responsive to antiangiogenic therapies as these tumors are highly vascularized and overexpress angiogenic factors. Thalidomide exhibits antiangiogenic activity and may provide additive or synergistic antitumor effects when given concurrently with temozolomide, an alkylating agent. To further evaluate this new concept of combining an antiangiogenic with an alkylating agent, efficacy and tolerability of thalidomide alone and in combination with temozolomide were explored in a single-institution, nonrandomized open-label phase II study.

Patients and methods: Forty-four patients with GBMs, who received thalidomide for a period of at least three months, were evaluated for survival, time to tumor progression (TTP), and side effects. Microsurgical tumor extirpation and radiotherapy preceded chemotherapy. Nineteen patients (43%) received thalidomide only (T), and 25 patients (57%) had a combined chemotherapy of thalidomide and temozolomide (TT). Median thalidomide dosage was 200 mg/day. Median temozolomide dosage was 200 mg/m2/day for five days, in monthly cycles. Neuroradiological outcomes were assessed by a semiquantitative grading system.

Results: Median survival was 103 weeks (95% CI, 65–141 weeks) for TT-patients and 63 weeks (95% CI, 49–77 weeks) for T-patients (p <  0.01). Median TTP for the TT-group was 36 weeks (95% CI, 20–52 weeks) and 17 weeks (95% CI, 13–21 weeks) for the T-group (p <  0.06). Neuroradiologically, 14 patients (56%) of the TT-group and six (32%) of the T-group had evidence of stable disease on at least two successive neuroradiological follow-ups. Progressive disease was found in nine patients (36%) of the TT-group and in 13 (68%) of the T-group. In two patients (8%) of the TT-group, a response with tumor regression was found. Thalidomide and concurrent temozolomide were safe and well tolerated with mild to moderate toxicities.

Conclusions: The combination of thalidomide and temozolomide in the treatment of GBM appears to be more effective than that of thalidomide alone with respect to survival, TTP, and neuroradiological documentation of progression, stable disease or response. Further concurrent prospective studies of these agents in a larger group of patients with GBM will be required to establish the soundness of these intriguing observations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190–198, 2001

    CAS  PubMed  Google Scholar 

  2. Nieder C, Grosu AL, Molls M: A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26: 397–409, 2000

    CAS  PubMed  Google Scholar 

  3. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572, 1999

    CAS  PubMed  Google Scholar 

  4. Surawics TS, Davis F, Freels S, Laws ER Jr, Menck HR: Brain tumor survival: results from the National Cancer Data Base. J Neuro-Oncol 40: 151–160, 1998

    Google Scholar 

  5. Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 27: 1–10, 2000

    CAS  PubMed  Google Scholar 

  6. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011–1018, 2002

    CAS  PubMed  Google Scholar 

  7. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K: Extirpation of glioblastomas. MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 14: 77–87, 1993

    CAS  PubMed  Google Scholar 

  8. Shrieve DC, Alexander E III, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS: Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72–77, 1999

    CAS  PubMed  Google Scholar 

  9. Schiffer D, Chio A, Giordana MT, Mauro A, Migheli A, Vigliani MC: The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol (Berl) 77: 369–378, 1989

    CAS  Google Scholar 

  10. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848, 1992

    Article  CAS  PubMed  Google Scholar 

  11. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085, 1994

    PubMed  Google Scholar 

  12. Fine HA, Figg WD, Jaeckle K, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708–715, 2000

    CAS  PubMed  Google Scholar 

  13. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neuro-Oncol 54: 31–38, 2001

    Article  CAS  Google Scholar 

  14. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neuro-Oncol 51: 41–45, 2001

    Article  CAS  Google Scholar 

  15. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236–2241, 1996

    CAS  PubMed  Google Scholar 

  16. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588–593, 2000

    Article  CAS  PubMed  Google Scholar 

  17. Stupp R, Dietrich PY, Ostermann KS, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375–1382, 2002

    Article  CAS  PubMed  Google Scholar 

  18. Marx J: Angiogenesis.Aboost for tumor starvation. Science 301: 452–454, 2003

    CAS  PubMed  Google Scholar 

  19. Adlard JW: Thalidomide in the treatment of cancer. Anticancer Drugs 11: 787–791, 2000

    CAS  PubMed  Google Scholar 

  20. Singhal S, Mehta J: Thalidomide in cancer: potential uses and limitations. BioDrugs 15: 163–172, 2001

    Article  CAS  PubMed  Google Scholar 

  21. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990

    CAS  PubMed  Google Scholar 

  22. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavanee WK: Pathology and Genetics: Tumours of the Nervous System. IARC Press (International Agency for Research on Cancer), Lyon, France 2000, pp 29–39

    Google Scholar 

  23. Wesseling P, Ruiter DJ, Burger PC: Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neuro-Oncol 32: 253–265, 1997

    Article  CAS  Google Scholar 

  24. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4: 39–43, 2002

    Article  CAS  PubMed  Google Scholar 

  25. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, Karp CL: Inhibition of IL-12 production by thalidomide. J Immunol 159: 5157–5161, 1997

    CAS  PubMed  Google Scholar 

  26. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L: Thalidomide and thrombosis. Ann Dermatol Venereol 127: 171–174, 2000

    CAS  PubMed  Google Scholar 

  27. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV: Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33: 1592–1596, 1997

    Article  CAS  PubMed  Google Scholar 

  28. Marras LC, Geerts WH, Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89: 640–646, 2000

    Article  CAS  PubMed  Google Scholar 

  29. Chisholm RA, Stenning S, Hawkins TD: The accuracy of volumetric measurement of high-grade gliomas. Clin Radiol 40: 17–21, 1989

    CAS  PubMed  Google Scholar 

  30. Xue D, Albright RE Jr: Preoperative anaplastic glioma tumor volume effects on patient survival. J Surg Oncol 72: 199–205, 1999

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Zurich, Zurich, Switzerland

    Fabian Baumann, Miroslava Bjeljac, Yasuhiro Yonekawa & René L. Bernays

  2. Institute of Neuroradiology, University of Zurich, Zurich, Switzerland

    Spyros S. Kollias

  3. Department of Radiation Oncology, University of Zurich, Zurich, Switzerland

    Brigitta G. Baumert

  4. Department of Neuropathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Sebastian Brandner

  5. Department of Biostatistics, University of Zurich, Zurich, Switzerland

    Valentin Rousson

Authors
  1. Fabian Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miroslava Bjeljac
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Spyros S. Kollias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brigitta G. Baumert
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sebastian Brandner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Valentin Rousson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuhiro Yonekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. René L. Bernays
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baumann, F., Bjeljac, M., Kollias, S.S. et al. Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme. J Neurooncol 67, 191–200 (2004). https://doi.org/10.1023/B:NEON.0000021803.01170.03

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:NEON.0000021803.01170.03

Search

Navigation